HER2.CAR T-cells showed improved cell persistence compared to B7-H3.CAR T-cells against EPN cells, enhancing therapeutic potential.
The effectiveness of CAR T-cells against ependymomas is limited by tumor size and the overall immune response within the tumor environment.
Studies indicate that tumor size affects CAR T-cell activity, potentially reducing their efficacy in larger tumors, a concern for treating ependymomas.
Improving CAR T-cell expansion and persistence is crucial for combating ependymomas, particularly in the context of immune suppression.
Resumen
Figure S12 shows improved expansion and persistence of HER2.CAR T-cells over B7-H3.CAR T-cells against EPN cells.